224 related articles for article (PubMed ID: 25868510)
41. Strontium ranelate improves bone microarchitecture in osteoporosis.
Hamdy NA
Rheumatology (Oxford); 2009 Oct; 48 Suppl 4():iv9-13. PubMed ID: 19783592
[TBL] [Abstract][Full Text] [Related]
42. Strontium ranelate and risk of vertebral fractures in frail osteoporotic women.
Rolland Y; Abellan Van Kan G; Gillette-Guyonnet S; Roux C; Boonen S; Vellas B
Bone; 2011 Feb; 48(2):332-8. PubMed ID: 20817053
[TBL] [Abstract][Full Text] [Related]
43. Strontium ranelate as an adjuvant for fracture healing: clinical, radiological, and ultrasound findings in a randomized controlled study on wrist fractures.
Scaglione M; Fabbri L; Casella F; Guido G
Osteoporos Int; 2016 Jan; 27(1):211-8. PubMed ID: 26294293
[TBL] [Abstract][Full Text] [Related]
44. Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study.
Reginster JY; Seeman E; De Vernejoul MC; Adami S; Compston J; Phenekos C; Devogelaer JP; Curiel MD; Sawicki A; Goemaere S; Sorensen OH; Felsenberg D; Meunier PJ
J Clin Endocrinol Metab; 2005 May; 90(5):2816-22. PubMed ID: 15728210
[TBL] [Abstract][Full Text] [Related]
45. Strontium ranelate and alendronate have differing effects on distal tibia bone microstructure in women with osteoporosis.
Rizzoli R; Laroche M; Krieg MA; Frieling I; Thomas T; Delmas P; Felsenberg D
Rheumatol Int; 2010 Aug; 30(10):1341-8. PubMed ID: 20512336
[TBL] [Abstract][Full Text] [Related]
46. Cost-utility of long-term strontium ranelate treatment for postmenopausal osteoporotic women.
Hiligsmann M; Bruyère O; Reginster JY
Osteoporos Int; 2010 Jan; 21(1):157-65. PubMed ID: 19350339
[TBL] [Abstract][Full Text] [Related]
47. Cardiovascular safety of strontium ranelate: real-life assessment in clinical practice.
Donneau AF; Reginster JY
Osteoporos Int; 2014 Feb; 25(2):397-8. PubMed ID: 24322477
[No Abstract] [Full Text] [Related]
48. Strontium ranelate in osteoporosis.
Reginster JY
Curr Pharm Des; 2002; 8(21):1907-16. PubMed ID: 12171530
[TBL] [Abstract][Full Text] [Related]
49. Monitoring strontium ranelate therapy in patients with osteoporosis.
Kendler DL; Adachi JD; Josse RG; Slosman DO
Osteoporos Int; 2009 Jul; 20(7):1101-6. PubMed ID: 19266136
[TBL] [Abstract][Full Text] [Related]
50. Hip cortical thickness assessment in postmenopausal women with osteoporosis and strontium ranelate effect on hip geometry.
Briot K; Benhamou CL; Roux C
J Clin Densitom; 2012; 15(2):176-85. PubMed ID: 22321661
[TBL] [Abstract][Full Text] [Related]
51. Strontium ranelate in the prevention of osteoporotic fractures.
Reginster JY; Malaise O; Neuprez A; Bruyere O
Int J Clin Pract; 2007 Feb; 61(2):324-8. PubMed ID: 17263720
[TBL] [Abstract][Full Text] [Related]
52. Strontium ranelate in post-menopausal osteoporosis.
Przedlacki J
Endokrynol Pol; 2011; 62(1):65-72. PubMed ID: 21365582
[TBL] [Abstract][Full Text] [Related]
53. Strontium ranelate enhances callus strength more than PTH 1-34 in an osteoporotic rat model of fracture healing.
Habermann B; Kafchitsas K; Olender G; Augat P; Kurth A
Calcif Tissue Int; 2010 Jan; 86(1):82-9. PubMed ID: 19960189
[TBL] [Abstract][Full Text] [Related]
54. A new treatment for post-menopausal osteoporosis: strontium ranelate.
Rizzoli R
J Endocrinol Invest; 2005; 28(8 Suppl):50-7. PubMed ID: 16323829
[TBL] [Abstract][Full Text] [Related]
55. Short-term hemostatic safety of strontium ranelate treatment in elderly women with osteoporosis.
Halil M; Cankurtaran M; Yavuz BB; Ulger Z; Piskinpasa S; Gedik A; Haznedaroglu IC; Kirazli S; Ariogul S
Ann Pharmacother; 2007 Jan; 41(1):41-5. PubMed ID: 17179188
[TBL] [Abstract][Full Text] [Related]
56. [Suitability of strontium ranelate in a health care management area after drug surveillance alerts].
Cantudo-Cuenca MR; Calvo-Cidoncha E; Robustillo-Cortés MA; Saborido-Cansino MC; Gómez-Estrella G; Sánchez-Pedrosa A
Aten Primaria; 2016 Jan; 48(1):49-53. PubMed ID: 25900199
[TBL] [Abstract][Full Text] [Related]
57. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis.
Meunier PJ; Roux C; Seeman E; Ortolani S; Badurski JE; Spector TD; Cannata J; Balogh A; Lemmel EM; Pors-Nielsen S; Rizzoli R; Genant HK; Reginster JY
N Engl J Med; 2004 Jan; 350(5):459-68. PubMed ID: 14749454
[TBL] [Abstract][Full Text] [Related]
58. Efficacy and safety of oral strontium ranelate for the treatment of knee osteoarthritis: rationale and design of randomised, double-blind, placebo-controlled trial.
Cooper C; Reginster JY; Chapurlat R; Christiansen C; Genant H; Bellamy N; Bensen W; Navarro F; Badurski J; Nasonov E; Chevalier X; Sambrook PN
Curr Med Res Opin; 2012 Feb; 28(2):231-9. PubMed ID: 22148897
[TBL] [Abstract][Full Text] [Related]
59. Clinical effects of strontium ranelate in women with postmenopausal osteoporosis.
Delmas PD
Osteoporos Int; 2005 Jan; 16 Suppl 1():S16-9. PubMed ID: 15578158
[TBL] [Abstract][Full Text] [Related]
60. Strontium ranelate: a new paradigm in the treatment of osteoporosis.
Reginster JY; Lecart MP; Deroisy R; Lousberg C
Expert Opin Investig Drugs; 2004 Jul; 13(7):857-64. PubMed ID: 15212623
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
